Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial -

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Haematological disorders
Summary
In this non-inferiority RCT (n=230) 1 year progression free survival (PFS) was 0.76 with bendamustine plus rituximab vs 0.48 for fludarabine plus rituximab (non-inferiority for bendamustine p<0.0001).
UKMi comment
At median follow up of 96 months median PFS was 34.2 months for bendamustine plus rituximab vs 11.7 for fludarabine plus rituximab (HR 0.54; 95% CI = 0.38 to 0.72).
Related links: